Pelthos Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS · (Unaudited) | ||
| Cash and cash equivalents | $31,976 | $17,973 |
| Restricted cash, current | 250 | 50 |
| Accounts receivable, net | 11,700 | 8,858 |
| Inventory, net | 23,418 | 23,574 |
| Prepaid expenses and other current assets | 2,457 | 2,955 |
| Total current assets | 69,801 | 53,410 |
| Property and equipment, net | 9,310 | 9,586 |
| Operating lease right-of-use assets, net | 3,146 | 3,250 |
| Intangible assets, net | 38,440 | 39,470 |
| Goodwill | 24,681 | 24,681 |
| Total assets | $145,378 | $130,397 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Accounts payable | $6,147 | $2,986 |
| Accrued expenses | 12,835 | 15,364 |
| Contingent consideration | 1,000 | 2,200 |
| Operating lease liabilities, current portion | 640 | 635 |
| Deferred revenue, current portion | 978 | 966 |
| Other liabilities | 3,403 | 3,842 |
| Total current liabilities | 25,003 | 25,993 |
| Operating lease liabilities, net of current portion | 2,652 | 2,752 |
| Deferred revenue, net of current portion | 1,027 | 1,280 |
| Convertible debt | 23,283 | 31,441 |
| Venture loan and security agreement, net | 26,356 | — |
| Other long-term liabilities | 31,955 | 30,050 |
| Total liabilities | 110,276 | 91,516 |
| Commitments and contingencies (Note 12) | ||
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock Series A, $0.0001 par value, 150,000 shares authorized, 55,218 shares issued and outstanding as of March 31, 2026 and 150,000 shares authorized, 56,418 shares issued and outstanding as of December 31, 2025, respectively | — | — |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 3,369,911 and 3,234,423 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Additional paid in capital | 106,945 | 103,675 |
| Accumulated other comprehensive income | 3,189 | — |
| Accumulated deficit | (75,032) | (64,794) |
| Total stockholders' equity | 35,102 | 38,881 |
| Total liabilities and stockholders' equity | $145,378 | $130,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.